Oncology Corporate Profile
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|BL-8040||CXCR4 peptide inhibitor||Various cancer types||II|
|BL-8040||CXCR4 peptide inhibitor||Acute Myelogenous Leukemia (AML)||I||Genentech/Roche|
|AGI-134||immunotherapy||Various cancer types||Preclinical|
View additional information on product candidates here »
4/3/2017 01:03 pm
[Accesswire] - NEW YORK, NY / ACCESSWIRE / April 3, 2017 / Both companies have recently announced new public offerings and have gained the attention of investment rating firms. RDI Initiates Coverage: Bioline RX Ltd. ...